


Transforming imaging data into actionable predictions

We design pioneering tools that unlock
imaging data to improve patient outcomes



Company at a glance

At Quibim, we unlock the potential of imaging data to revolutionize personalized medicine. Our mission is to create pioneering tools that uncover the hidden data within medical images to understand each patient's unique imaging characteristics better.

By transforming imaging data into actionable predictions, we are committed to enhancing clinical decision-making and driving innovation in medical imaging.

CERTIFICATIONS AND COMPLIANCE

- ISO 13485:2016
- ISO/IEC 27001:2022
- NATIONAL SECURITY FRAMEWORK (ENS)
- HIPAA
- GDPR
- FDA / CE / UKCA REGULATORY CLEARANCES

100K+

Anonymized Patient Data

\$70M+

in Funding Raised

230+

Sites Worldwide

350+

Scientific Publications

Our AI solutions

QP-Prostate®

QP-Prostate® is an AI-powered solution that improves radiological assessments for prostate cancer.

It automates prostate magnetic resonance imaging (MRI) analysis, improving lesion detection and diagnosis (CADe/CADx) with pathology-trained AI models. This enables precise risk assessment and more informed clinical decision-making, improving patient outcomes.




510(k) UK CE
K203582 0086 2797
K242683

Detect and diagnose prostate cancer



- AI algorithms trained on pathology data as ground truth, significantly enhancing radiologists' capabilities in detecting aggressive prostate cancers that traditional methods might miss.
- Lesion detection module powered by biopsy-trained AI models highlights high- and moderate-risk areas for clinically significant prostate cancer lesions.
- Advanced imaging techniques to accurately identify prostate lesions and deliver robust risk assessment, supporting timely and precise diagnosis and patient care.
- AI-driven segmentation for precise delineation of the prostate gland and seminal vesicles, and accurate identification of lesions.
- Automated image quality evaluation, ensuring consistency and reliability in prostate MRI assessments.
- Regulatory compliance. FDA 510(k) cleared, CE-marked, and UKCA-marked, ensuring safe clinical use in multiple regions.



QP-Brain®

QP-Brain® is an AI-powered tool that automates detecting, quantifying, and monitoring brain atrophy and white matter lesions in brain MRIs. It provides radiologists with reproducible, data-driven insights for improved patient management and generates comprehensive radiological reports to support precision medicine.



510(k) UK CE
K232231 0086 2797

QP-Liver®

QP-Liver® is an AI-driven solution for optimizing the diagnosis and monitoring of diffuse liver diseases.

It leverages high-precision tissue fat and iron quantification from MRI scans, enabling early disease detection and personalized treatment planning.



UK CE
0086 2797

QP-Insights®

QP-Insights is an advanced cloud-based platform that optimizes imaging data management in clinical trials and research.


It enhances drug development programs and boosts the success of clinical trials by improving data accessibility, structuring and exploitation, and by identifying the right patients for the right trials.



Quantitative brain MRI analysis



- Objective longitudinal reporting for tracking disease progression and treatment response.
- Versatile and scalable solution, adaptable to various clinical settings, including community hospitals.
- Streamlined workflows that enhance operational efficiency and reduce radiologist workload.
- Regulatory compliance: FDA 510(k) cleared, CE-marked, and UKCA-marked, ensuring safe clinical use across multiple regions.



Noninvasive liver disease assessment




- Automated liver segmentation for accurate and reproducible organ analysis.
- Quantitative assessment correlating fat and iron levels with reference pathological standards.
- Supports early diagnosis and disease monitoring, aiding clinicians and researchers in optimizing patient management.
- Regulatory compliance. CE-marked and UKCA-marked, ensuring clinical availability in Europe and the UK.



Take control of your imaging data



- Automated imaging data processing with AI-driven lesion detection, segmentation, and radiomics-based quantitative analysis.
- Better patient stratification to identify treatment-responsive populations.
- Optimized trial design supporting adaptive clinical studies and real-world evidence (RWE), while facilitating cohort enrichment.
- Regulatory-compliant data structuring ensures secure, role-based access control.



Why choose Quibim?

1

Trusted partner in drug development

Expertise in imaging biomarkers that support precision medicine and accelerate therapeutic innovation.

2

Advanced AI and data science

Technology designed to streamline research workflows and empower evidence-based clinical decision-making.

3

Accelerating translational impact


We help you unlock the full value of imaging data, clinical context, and radiomic insights to accelerate innovation in care and research.

Main users



Pharmaceutical companies

With predictive and prognostic models, they design clinical trials to improve the safety and efficacy of new drugs.




Research centers

They use the platform to analyze large datasets and drive new research forward.



Equipment manufacturers

MRI, CT, and PET equipment integrate algorithms and software into their hardware to process and interpret images.



Hospital centers

They use radiomics to enhance diagnostic accuracy and improve patient care.

Contact us: contact@quibim.com

USA: Life Sciences: +1 718.308.1418 / SaMD: +1 347.819.3602

Europe: +34 961 243 225

